2023 Smart People Grand Award

Cognitact Limited

Protein Biomarkers for Assessing Alzheimer's Disease

Description of Entry:
Cognitact specializes in the development of solutions of early screening and staging of Alzheimer's disease (AD) using blood-based biomarkers. The primary test service, PlasmarkADTM, utilizes world-leading proteomic technology to detect the level change of 21 AD-related protein biomarkers from a small volume of venous blood, to evaluate the individual risk of developing AD, with an accuracy of over 96%. Combining proprietary machine-learning algorithms for data analysis, PlasmarkADTM is capable of detecting AD risk 5 to 10 years before symptoms manifest. Moreover, the technology employs a multi-dimensional analysis approach, evaluating the status of different human body systems related to AD, including the immune, metabolic, neural, and vascular systems, which provides a holistic understanding of the disease progression and facilitates the patient stratification. In summary, through the comprehensive blood biomarker profiling, Cognitact provides a solution for early screening of AD cases, which facilitates for early intervention and disease management. It also serves as an assisted tool for clinical consideration of disease monitoring and precision medicine, ultimately benefiting the ageing society.

(Information is provided by awardee)


Comments from Judging Panel:
The assessment's use of distinctive biomarkers for identification and big data analysis through non-invasive screening is promising. It demonstrates a good application of technology in ageing society. The assessment can not only assist medical staff in further diagnosis and early intervention for treatment, but also adopt active health management.

Website of Entry: https://www.cognitact.com/